5 Alarm Bio Ltd raises £500K in seed round
British anti-aging therapeutics developer 5 Alarm Bio Ltd has raised £500K in a seed financing for testing its lead compound FAB001 for healing chronic wounds.
High blood pressure reprograms immune system
Interferon-gamma overexpression leads to hypertension-induced damage to the blood-brain barrier by reprogrammed macrophages.
Abivax SA raises 130m to advance obefazimod to Phase III
French Abivax SA has raised 130m capital led by TCGX to accelerate Phase III testing of its ulcerative colitis candidate obefazimod extend its cashflow.
PVH Corp joins fiber-to-fiber consortium
PVH Corp has joined fiber-to-fiber consortium that wants to make textile recycling sustainable by establishing standards for biorecycled textile fibre.
Free sugar linked to higher cardiovascular disease
A UK Biobank study suggests that higher intake of free sugars is associated with a higher risk to develop cardiovascular disease, UK researchers report in BMC Medicine.
AMsilk scaling up through Evonik collaboration
Fermatation expert Evonik SE has entered into an agreement with the German recombinant silk producer AMSilk to produce industrial quantities of innovative, sustainable silk proteins.
HOOKIPA bags US$10m cancer milestone
HOOKIPA has received a US$10m milestone under its 2022 agreement with Roche to develop an arenaviral immunotherapy for KRAS-mutated cancers.
Cydar Medical Ltd raises 10.5m in Series A financing
Cambridge-based endovascular surgical AI specialist Cydar Medical has completed a 10.5m (£9.3m) Series A funding round led by Pembroke Venture Capital Trust
Evonetix extends Series B financing to US$54m
British Evonetix Ltd has added US$$24m to its existing US$30m Series B financing round. The new financing was led by existing investor Foresite Capital.
Germanys Curevac offers common shares
mRNA vaccine pioneer CureVac N.V. has announced that it will sell US$200m of its common shares in an underwritten public offering.